These findings indicate that while curcumin itself interacts with COX-2 and potentially inhibits its function, its analog CDF shows a more substantial binding affinity, suggesting a higher potential for therapeutic use in conditions where COX-2 inhibition is beneficial, such as in certain types of cancer and inflammatory diseases. This evidence concerns the gene PTGS2 and cancer.